RUBY: dostarlimab in combination with carboplatin-paclitaxel compared with placebo and carboplatin-paclitaxel in patients with primary advanced or first recurrent endometrial cancer

AZUR-1: dostarlimab monotherapy in patients with untreated stage II/III dMMR/MSI-H  locally advanced rectal cancer

AZUR-2: dostarlimab perioperative monotherapy in patients with untreated T4N0 or stage III dMMR/MSI-H resectable colon cancer

GLIOFOCUS: study comparing the clinical efficacy and safety of niraparib with temozolomide in adult participants with newly-diagnosed, MGMT unmethylated glioblastoma

GALAXIES H&N-202: study evaluating novel immunotherapy combinations as first-line treatment of PD-L1-positive, recurrent/metastatic HNSCC

JADE: study to evaluate dostarlimab as sequential therapy after chemoradiation in participants with locally advanced unresected head and neck squamous cell carcinoma

PERLA: dostarlimab with chemotherapy vs pembrolizumab with chemotherapy in metastatic nonsquamous NSCLC

ENTRÉE-Lung: platform trial of novel regimens versus standard of care in NSCLC

NCT05565378: platform study utilizing a master protocol to evaluate novel immunotherapy combinations in patients with previously untreated, locally advanced unresectable or metastatic, PD-L1-selected non-small cell lung cancer

GALAXIES-LUNG-201: platform study utilizing a master protocol to evaluate of novel immunotherapy combinations in patients with previously untreated, locally advanced unresectable/metastatic, PD-L1–selected NSCLC

COSTAR Lung: cobolimab in combination with dostarlimab and docetaxel in advanced NSCLC that has progressed on prior anti-PD-(L)1 therapy and chemotherapy 

ZEAL-1L: niraparib with pembrolizumab vs placebo with pembrolizumab as maintenance therapy in NSCLC

COSTAR Lung: cobolimab in combination with dostarlimab and docetaxel in advanced NSCLC that has progressed on prior anti-PD-(L)1 therapy and chemotherapy 

DREAMM-5: platform study of belantamab mafodotin alone and in combination with GSK3174998 (OX40 agonist antibody), feladilimab (ICOS agonist IgG4 antibody), nirogacestat alone or in combination with Rd or Pd, dostarlimab (anti-PD-1 antibody), or isatuximab in patients with relapsed/refractory multiple myeloma

DREAMM-9: belantamab mafodotin in combination with bortezomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma who are ineligible for ASCT

DREAMM-11: a dose-escalation study of belantamab mafodotin in Japanese patients with relapsed/refractory multiple myeloma

DREAMM-12: a pharmacokinetics and safety study of belantamab mafodotin in patients with relapsed/refractory multiple myeloma who have normal or varying degrees of impaired renal function 

DREAMM-13: a pharmacokinetics and safety study of belantamab mafodotin in patients with relapsed/refractory multiple myeloma who have normal or varying degrees of impaired hepatic function 

DREAMM-20: study to investigate the safety and efficacy of GSK2875914 as monotherapy and in combination with other treatments in patients with multiple myeloma 

DREAMM-6: study to investigate alternative dosing regimens of belanatamab mafodotin in patients with relapsed/refractory multiple myeloma 

DREAMM-14: study to investigate alternative dosing regimens of belantamab mafodotin in patients with relapsed/refractory multiple myeloma 

DREAMM-5: platform study of belantamab mafodotin alone and in combination with GSK3174998 (OX40 agonist antibody), feladilimab (ICOS agonist IgG4 antibody), nirogacestat alone or in combination with Rd or Pd, dostarlimab (anti-PD-1 antibody), or isatuximab in patients with relapsed/refractory multiple myeloma

DREAMM-20: study to investigate the safety and efficacy of GSK2875914 as monotherapy and in combination with other treatments in patients with multiple myeloma 

DREAMM-7: belantamab mafodotin in combination with bortezomib and dexamethasone compared with daratumumab, bortezomib, and dexamethasone in patients with relapsed/refractory multiple myeloma

DREAMM-8: belantamab mafodotin in combination with pomalidomide and dexamethasone vs pomalidomide, bortezomib, and dexamethasone in relapsed/refractory multiple myeloma 

NCT04549363: Characterization of corneal epithelial changes in patients with relapsed/refractory multiple myeloma treated with belantamab mafodotin 

NCT0344113: extended access of momelotinib in patients with primary myelofibrosis or post-polycythemia vera/post-essentail thrombocythemia myelofibrosis 

GARNET~: dose-escalation and ‑expansion study in patients with advanced solid tumors

NCT04446351: first-time-in-human study of Nelistotug as monotherapy and in combination with dostarlimab with or without belrestotug in advanced solid tumors

NCT03329001: a crossover bioavailability and bioequivalence study of niraparib tablet and capsule formulation in patients with advanced solid tumors

NCT05277051: first-time-in-human, open label study of GSK4381562 administered as monotherapy, in combination with dostarlimab, or in combination with dostarlimab and belrestotug in patients with selected advanced solid tumors 

AMBER§: dose-escalation and -expansion study of cobolimab alone or in combination with other anticancer agents in patients with advanced solid tumors

TIG-006¶: study of belrestotug in combination with standard of care or investigational therapy in advanced solid tumors

NCT06077877: study to determine maximum tolerated dose of GSK4524101 as monotherapy and in combination with niraparib in patients with solid tumors

Long-term treatment-extension study in patients who have completed a prior GSK-sponsored niraparib study

PAVO£: niraparib as monotherapy in the treatment of patients with locally advanced or metastatic solid tumors with a PALB2 mutation

NCT04641247: a long-term treatment-extension study of niraparib in patients who have completed a prior GSK-sponsored niraparib study 

TIG-006¶: study of belrestotug in combination with standard of care or investigational therapy in advanced solid tumors 

NCT06077877: study to determine maximum tolerated dose of GSK4524101 as monotherapy and in combination with niraparib in patients with solid tumors 

OPAL: study of treatment with niraparib in combination with dostarlimab and bevacizumab in patients with ovarian cancer

OPAL: study of treatment with niraparib in combination with dostarlimab and bevacizumab in patients with ovarian cancer

OVARIO: study of first-line maintenance therapy with niraparib and bevacizumab following response on front-line platinum-based chemotherapy and bevacizumab in patients with advanced ovarian cancer

Long-term treatment-extension study in patients who have completed a prior GSK-sponsored niraparib study

OPAL: study of treatment with niraparib in combination with dostarlimab and bevacizumab in patients with ovarian cancer

OPAL: study of treatment with niraparib in combination with dostarlimab and bevacizumab in patients with ovarian cancer

FIRST†: study of niraparib alone or in combination with dostarlimab and/or bevacizumab as maintenance therapy following first-line treatment with platinum-based chemotherapy alone or in combination with dostarlimab and/or bevacizumab in newly diagnosed advanced ovarian cancer

FIRST†: study of niraparib alone or in combination with dostarlimab and/or bevacizumab as maintenance therapy following first-line treatment with platinum-based chemotherapy alone or in combination with dostarlimab and/or bevacizumab in newly diagnosed advanced ovarian cancer